Tafamidis ATTR denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Tafamidis for ATTR Cardiomyopathy on Medical-Necessity Grounds

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease in which misfolded transthyretin protein deposits accumulate in the heart muscle. Tafamidis is FDA-approved specifically for this condition and is the only disease-modifying therapy in its class. Despite that, Aetna medical-necessity denials are common because the insurer requires evidence that a patient meets specific diagnostic and clinical criteria before approving coverage. Reviewers frequently deny claims when records do not explicitly document how the diagnosis was established, what prior treatments were attempted, or how severe the condition is.

## Your Federal Appeal Rights

You have layered federal protections:

• ACA §2719 / State External Review: If Aetna upholds its denial internally, you may request an independent external review by a certified Independent Review Organization (IRO). This right generally must be exercised within approximately four months of the final internal denial notice — check your Explanation of Benefits for the exact deadline.
• ERISA §503 (employer-sponsored plans): You are entitled to a full-and-fair review, written reasons for denial citing the specific plan language and clinical basis, and the right to submit rebuttal evidence.
• Expedited Review: If your condition is urgent or your health could deteriorate while waiting, request an expedited internal and external review simultaneously — decisions are typically required within 72 hours.

## Concrete Appeal Steps and Timeline

1. Request the denial letter and the specific coverage criteria Aetna applied (you are entitled to this in writing). 2. Obtain Aetna's published Clinical Policy Bulletin for tafamidis — read every requirement. 3. File a Level 1 internal appeal within the deadline shown on your denial notice (commonly 180 days). 4. If denied again, file a Level 2 appeal or proceed directly to external review. 5. Parallel-track: ask your prescriber to submit a peer-to-peer review request with Aetna's medical director.

## Documentation to Gather

• Confirmed ATTR-CM diagnosis: pathology or imaging report (e.g., nuclear scintigraphy or endomyocardial biopsy), genetic testing results distinguishing wild-type from hereditary variant.
• Cardiac functional severity: echocardiogram reports, functional classification per your cardiologist's chart notes, any relevant biomarker trend data.
• Prior treatment history: dates, agents tried, outcomes, and reasons for inadequacy or discontinuation.
• Prescriber letter of medical necessity: should explain why tafamidis is appropriate for this patient's specific disease stage and why alternatives are insufficient.
• Relevant guideline support: reference the applicable ACC/AHA heart failure guidelines generically — your cardiologist can cite the relevant society recommendations without you needing to quote trial statistics.

## Criteria-Mapping Structure

Copy each requirement from Aetna's Clinical Policy Bulletin into a table. For each requirement, record the exact supporting fact from the medical record — the date, the test result description, and the treating physician's conclusion. Submit this mapping as a cover sheet on your appeal so the reviewer can verify compliance line by line without having to search through the record.